Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 8 PART2, 2008, Pages

  Fujimoto, Tomoko ^a   Tomimatsu, Masahiko ^a   Iga, Daijiro ^a   Endo, Hitoshi ^a   Otsuka, Kuniaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon alpha 2b; Ribavirin; Th1 Th2 ratio

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CELL RATIO; CELL STRUCTURE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRULENCE;

EID: 48549087097     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05320.x     Document Type: Article

References (16)

1. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon alpha therapy in hepatitis C virus infection. Hepatology 1994 19 : 1088 94.
2. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998 339 : 1485 92.
3. Bodenheimer HC Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997 26 : 473 7.
4. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998 351 : 83 6.
5. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon-alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 32.
6. Cramp ME, Rossol S, Chokshi S et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000 118 : 346 55.
7. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone: definition according to profiles of cytokine activity and secreted proteins. J. Immunol. 1986 136 : 2348 57.
8. Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991 254 : 279 82.
9. Ando K, Hiroishi K, Kaneko T et al. Perforin, Fas/Fas ligand, and TNF-α pathway as specific and bystander killing mechanism of hepatitis C virus-specific human CTL. J. Immunol. 1997 158 : 5283 91.
10. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002 35 : 1002 9.
11. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type2-like T-helper cells in hepatitis C virus infection. Implication for hepatitis C virus chronicity. Hepatology 1997 25 : 449 58.
12. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996 24 : 759 65.
13. Reiser M, Marousis CG, Nelson DR et al. Serum interleukin 4 and interleukin 10 levels in patient with chronic hepatitis C virus infection. J. Hepatol. 1997 26 : 471 8.
14. Masaki N, Fukushima S, Hayashi S. Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig. Dis. Sci. 2002 10 : 2163 9.
15. Amarra R, Mareckova H, Urbank P, Fucikova T. Immunological predictors of different responses to combination therapy with interferonα and ribavirin in patients with chronic hepatitis C. J. Gastroenterol. 2003 38 : 254 9.
16. Cacciarelli TV, Martinez OZ, Gish R, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996 24 : 6 9.